Effect of Paclitaxel on PC-3 Cell Line Xenografted into Athymic Nude Mice.
- Author:
Suck Ho KANG
1
;
Jun CHEON
;
Duck Ki YOON
Author Information
1. Department of Urology, Korea University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Prostatic neoplasms;
Paclitaxel;
Xenograft model antitumor assays
- MeSH:
Animals;
Appointments and Schedules;
Body Weight;
Cell Line*;
Heterografts*;
Humans;
Male;
Mice;
Mice, Nude*;
Natural History;
Paclitaxel*;
Prostate;
Prostatic Neoplasms;
Survival Rate;
Tumor Burden;
Xenograft Model Antitumor Assays
- From:Korean Journal of Urology
2004;45(3):263-267
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Hormone-refractory prostate cancer(HRPC) is the terminal step in the natural history of prostate cancer, for which no chemotherapeutic agents have been shown to impact on the clinical outcomes. However, taxane-based therapies have recently appeared to have a significant efficacy on HRPC. The therapeutic effect of paclitaxel was evaluated against metastatic human prostate cancer PC-3 xenografted into athymic nude mice. MATERIALS AND METHODS: A total of 24 male nude mice subcutaneously transplanted with the PC3 cell line were divided in 2 groups. An experimental group was given paclitaxel intraperitoneally at a dose of 12.5mg/kg per injection per day for 4 consecutive days, from the 6th and 20th day following tumor injection. All mice were observed for 31 days, and sacrificed by CO2 gas asphyxiation at the end of the experiment. The mean tumor volume and body weight of both groups were compared using student's t-tests. A tumor volume of more than 200mm3 was regarded as dead. The survival rate was indirectly analyzed using the Kaplan-Meier method. RESULTS: The mean tumor volume of the paclitaxel treatment group was significantly reduced from the 20th day after tumor injection until the end of the experiment compared with the control group. The mean body weight of both groups was different significantly from the 17th day after tumor injection until the end of the experiment, but after removal of the tumor mass, at the 31st day after tumor injection, no significant difference was observed between the two groups. The survival rate of the paclitaxel treatment group was significantly higher than that of the control group. CONCLUSIONS: Our data has shown that paclitaxel is effective in suppressing the growth rate of a HRPC cell line in vivo and improved the survival rate. It is believe that further clinical assessment of the optimal dose and schedule of this drug are warranted.
